Source comparison
Sermorelin Support Testosterone Research: Comparison
Primary Action Stimulates endogenous GH release via GHRH receptor agonism Directly supplies exogenous testosterone Blocks estrogen receptors at pituitary to increase LH/FSH Sermorelin works upstream of both LH signaling and testicular synthesis—it's the most i
This comparison does not assign a generated winner or score.
- Primary Action
- Stimulates endogenous GH release via GHRH receptor agonism
- Directly supplies exogenous testosterone
- Blocks estrogen receptors at pituitary to increase LH/FSH
- Sermorelin works upstream of both LH signaling and testicular synthesis—it's the most indirect but least suppressive option
- Testosterone Increase
- 8–20% in hypogonadal men with GH deficiency
- 200–400% (dose-dependent, suppresses natural production)
- 30–80% (variable response, preserves natural production)
- Sermorelin's effect is conditional on intact pituitary-gonadal signaling; TRT guarantees elevation but suppresses endogenous pathways
- Effect on Endogenous Production
- Preserves and potentially enhances natural GH and LH pulsatility
- Suppresses LH, FSH, and spermatogenesis completely
- Maintains LH/FSH production by blocking estrogen feedback
- Sermorelin is the only option that doesn't interfere with downstream hormone signaling
- Onset of Effect
- 8–16 weeks for measurable testosterone change
- 2–4 weeks for symptom relief
- 4–12 weeks for hormone normalization
- Sermorelin requires the longest lead time because it relies on pituitary response and downstream pathway restoration
- Ideal Candidate
- Men with concurrent GH deficiency and low-normal testosterone (IGF-1 <150 ng/mL)
- Men with primary hypogonadism or severe testosterone deficiency (<300 ng/dL)
- Men with secondary hypogonadism who want to preserve fertility
- Sermorelin fits a narrow clinical window—optimizing one deficiency to improve another
- Regulatory Context
- Off-label use; sermorelin is FDA-approved for pediatric GH deficiency only
- FDA-approved for male hypogonadism when clinically indicated
- FDA-approved for female infertility; used off-label for male hypogonadism
- All three require prescriber oversight; sermorelin's legal availability for adult use varies by jurisdiction